Rabies Human Clinical Trial
Official title:
Evaluation With Rabies Vaccine (Vero Cell) of Two Different Immune Procedure in the Healthy Crowd the Immunogenicity and Safety of Randomized, Blinded, Similar Vaccine Against Ⅲ Phase of Clinical Trials
To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.
The trial to assess the rabies vaccine (Vero cells) in healthy group of 9 ~ 65 years old after inoculation, the first dose after 14 days and 14 days after inoculation 5 agent group turn antibody positive rate of bad effect on 5 agent in the control group; The safety profile, seroconversion rate, and geometric mean concentration of the four-dose vaccine were noninferior to those of the five-dose regimen at 14 days after the first dose. More people aged 9-65 in the first agent free after 7 days, 14 days and 14 days after inoculation, 5 patients and 5 doses in the control group, four patients and 5 doses group antibody positive rate, GMC and GMC growth multiples have differences. To evaluate whether the seroconversion rate of subjects in the 4-dose experimental group reached 100% 14 days after the whole course of vaccination. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05545371 -
Prevention of Rabies With Four Doses of Rabies Vaccine
|
Phase 3 | |
Completed |
NCT03557008 -
Responses to Rabies Vaccine in Adults With or Without Antibiotics
|
Phase 4 | |
Completed |
NCT05549908 -
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
|
Phase 3 | |
Completed |
NCT04495569 -
A Bridging Study of the SYN023 on Healthy Adult Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT05382650 -
Survey of Human Rabies Immune Globulin Safety in Children
|
||
Completed |
NCT04213950 -
Improving Adherence to Rabies PEP Guideline Recommendations
|
N/A |